BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23

• Press Releases

  Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

  October 15, 2026

   · 

  10 min read
• Press Releases

  Paradigm Clinical Research Expands into Nevada with New Las Vegas Clinical Trial Site

  October 15, 2026

   · 

  1 min read
• Press Releases

  IBA selected to support the US expansion of a leading radiopharmaceutical producer with an order for 12 Cyclone® KIUBE systems

  October 15, 2026

   · 

  3 min read
• Press Releases

  argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

  October 15, 2026

   · 

  1 min read
• Press Releases

  Kuros Biosciences increases 2026 annual guidance, The company reports 40% year-over-year increase in sales in the first nine months of 2026

  October 15, 2026

   · 

  5 min read
• Press Releases

  PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis

  October 15, 2026

   · 

  10 min read
• Press Releases

  OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare Conference

  October 15, 2026

   · 

  3 min read
• Press Releases

  OMass Therapeutics Announces $310 Million Series C Financing to Advance Portfolio of Small Molecule Therapeutics in Endocrinology and Immunology

  October 15, 2026

   · 

  4 min read
• Press Releases

  Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention

  October 15, 2026

   · 

  4 min read
• Press Releases

  Vividion Therapeutics Expands Clinical Development of WRN Inhibitor VVD-214 with Phase 2 Combination Study in First-Line Patients with Advanced Colorectal Cancer

  October 15, 2026

   · 

  5 min read